Literature DB >> 21420945

A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.

Sabine Weidensee1, Peter Goettig, Marko Bertone, Dorothea Haas, Viktor Magdolen, Marion Kiechle, Alfons Meindl, André B P van Kuilenburg, Eva Gross.   

Abstract

OBJECTIVES: Evaluation of a non-synonymous mutation associated with dihydropyrimidine dehydrogenase (DPD) deficiency. DESIGN AND METHODS: DPD enzyme analysis, mutation analysis and molecular dynamics simulations based on the 3D-model of DPD.
RESULTS: The substitution Lys63Glu is likely to affect the FAD binding pocket within the DPD protein and contributes to a near-complete DPD deficiency in a patient with developmental retardation.
CONCLUSIONS: Like other DPD variants attenuating FAD binding, Lys63Glu should be included in screening for DPD deficiency.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420945     DOI: 10.1016/j.clinbiochem.2011.03.033

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients.

Authors:  Wenhui Sun; Chungen Yan; Shaochang Jia; Jianhua Hu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing.

Authors:  Reynold C Ly; Remington E Schmidt; Patrick J Kiel; Victoria M Pratt; Bryan P Schneider; Milan Radovich; Steven M Offer; Robert B Diasio; Todd C Skaar
Journal:  JCO Precis Oncol       Date:  2020-06-12

3.  Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study.

Authors:  Paula Soria-Chacartegui; Gonzalo Villapalos-García; Luis A López-Fernández; Marcos Navares-Gómez; Gina Mejía-Abril; Francisco Abad-Santos; Pablo Zubiaur
Journal:  Pharmaceutics       Date:  2021-11-29       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.